cBAF Protein Complex Determines Immune Cell Destiny

In a study published in Immunity, Salk Institute Professor Susan Kaech and Associate Professor Diana Hargreaves have uncovered more details about cytotoxic T cells' ability to transform into effector and memory T cell subtypes. This transformation is crucial to the body's immune response to infections and diseases like cancer.

The researchers found that a protein complex called cBAF acts as a key regulator, controlling the opening or closing of genetic "doors" that determine the fate of these immune cells. This newfound understanding has significant implications for developing more effective vaccines and cancer therapeutics.

The team hypothesized that the cBAF complex, known for its role in chromatin remodeling in other cell types, might also influence cytotoxic T cell differentiation. To investigate this, they conducted experiments using mice infected with a virus to trigger the T cell immune response.

They found that the cBAF complex, particularly the subunit ARID1A, played a crucial role in rearranging chromatin, allowing transcription factors access to genetic instructions necessary for the development of different T cell subtypes. 

Without ARID1A, the cytotoxic T cells could not transform into the short-lived, rapid-response effector subtype. Additionally, the memory T cells formed without ARID1A responded less effectively to reinfections. Furthermore, the development of tissue-resident memory T cells depended entirely on ARID1A.

Professor Hargreaves emphasizes the importance of ARID1A, as its absence significantly impairs the body's ability to fight infections. For future work, the team wants to examine these mechanisms using human T cells and further investigate their impact on memory T cells.

By unraveling the intricate interplay between chromatin remodeling, genetic code accessibility, and transcription factors, scientists hope to optimize the functioning of immune cells for the development of innovative therapeutic approaches.